Ghrp 2.

Ghrp 2 is a research compound in the growth-hormone secretagogues.

Acting on the ghrelin / GH-secretagogue receptor to release growth hormone.

It draws interest for growth-hormone secretagogues.

D-tier evidence: human evidence is limited; most support is preclinical.

What it is

GHRP-2 (growth hormone-releasing peptide-2; international nonproprietary name pralmorelin; development codes KP-102/GPA-748) is a synthetic hexapeptide with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2. It belongs to the "classical" growth hormone secretagogue (GHS) family pioneered by Cyril Bowers in the 1980s and is a synthetic agonist of the ghrelin receptor. Unlike GHRH, it is structurally unrelated to any hypothalamic releasing hormone and instead mimics the endogenous gut peptide ghrelin.

How it works

GHRP-2 binds and activates the growth hormone secretagogue receptor type 1a (GHS-R1a), the same Gq/11-coupled receptor targeted by ghrelin, expressed on anterior-pituitary somatotrophs and in the hypothalamus (including the arcuate nucleus). Receptor activation drives phospholipase C signaling, IP3/DAG generation, and intracellular calcium release, evoking pulsatile GH secretion. Because it acts through a pathway distinct from (and synergistic with) GHRH, GHRP-2 and GHRH together produce a markedly larger GH pulse than either alone. Its action on hypothalamic ghrelin-receptor circuits also explains its orexigenic (appetite-stimulating) effect and a degree of off-target activation of the corticotroph and lactotroph axes.

What the evidence shows

Human pharmacology is well characterized for acute, single-dose use: controlled studies show GHRP-2 reliably triggers a robust GH pulse, and in healthy men it increased subjective hunger and food intake, confirming it behaves as a ghrelin mimetic (Laferrère et al., JCEM 2005). On the strength of acute diagnostic data it is approved in Japan as a single-dose GH-deficiency provocation test, where the GH response separates GH-sufficient from GH-deficient subjects. Critically, the long-term therapeutic program failed: development for treating GH-deficient children/pituitary dwarfism reached Phase II but was not brought to market, in part because the GH response to GHRP-2 is blunted in people with GH deficiency relative to healthy individuals. There are essentially no rigorous long-term human trials demonstrating benefit for body composition, muscle, anti-aging, or performance—claims in those areas rest on mechanism and short-term hormone changes, not proven clinical outcomes.

Safety considerations

Documented acute effects in human studies include off-target stimulation of ACTH and cortisol and a transient rise in prolactin, a feature that distinguishes GHRP-2 from the more selective secretagogue ipamorelin (Arvat et al., Peptides 1997). As a ghrelin-receptor agonist it predictably stimulates appetite, and sustained GH/IGF-1 elevation carries the theoretical risks associated with the GH axis (insulin resistance, fluid retention, joint discomfort). The fundamental safety gap is that GHRP-2 has been studied chiefly as a one-time diagnostic agent; the consequences of repeated or chronic non-clinical use—including effects on the HPA axis, glucose metabolism, and any proliferative risk from prolonged IGF-1 elevation—have not been established in controlled long-term human trials. Material sold for "research" use is unregulated and may differ in identity, purity, or sterility from pharmaceutical-grade product.

Regulatory status

Approved in Japan (marketed by Kaken Pharmaceutical as GHRP Kaken 100) solely as a single-dose diagnostic agent for assessing growth hormone deficiency—making it the only GHS ever granted national regulatory approval, and only for diagnosis, not therapy. It is not FDA-approved for any indication; in the United States and most jurisdictions it is investigational/research-use-only, and it is prohibited in sport under the WADA Prohibited List (S2, growth hormone secretagogues).

1. [1]Pralmorelin (GHRP-2) — drug profile: structure, ghrelin-receptor mechanism, and Japanese diagnostic approval — Wikipedia (encyclopedic overview with cited primary references)
2. [2]Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men — J Clin Endocrinol Metab, 2005; PMID 15699539
3. [3]Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man — Peptides, 1997; PMID 9285939
4. [4]GHRP-2 / pralmorelin — PubMed literature search (mechanism, diagnostic and endocrine studies) — PubMed query, NCBI

Stack fit

Why not C: held back by human evidence, safety clarity, regulatory clarity, practical relevance.

Why not F: supported by mechanism confidence.

What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.

What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.

• Ghrp 2 is not FDA-approved for human use; it is discussed in a research context.
• It belongs to the Growth-hormone secretagogues class.
• Its principal mechanism is characterized in the literature.

• Whether observed effects reliably translate to humans at large.
• Long-term safety in healthy users, and full drug-interaction risk.
• Optimal studied parameters outside any approved indication.
• Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
• Quality and purity of material from non-pharmaceutical sources.

1. What it is
2. The Ghrelin-receptor agonism mechanism
3. The preclinical evidence lane
4. Why Preliminary, and not higher or lower
5. Proven lane vs speculative lane
6. What people report
7. Regulatory status
8. What changed recently